Cargando…
Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
BACKGROUND: Artemisinin-based combination therapies (ACTs) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in all malaria endemic countries. Artemisinin resistance, partner drug resistance, and subsequent ACT failure are widespread in Southeast Asia. The more recent ind...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462557/ https://www.ncbi.nlm.nih.gov/pubmed/36083995 http://dx.doi.org/10.1371/journal.pone.0273249 |
_version_ | 1784787212169117696 |
---|---|
author | Tindana, Paulina Guissou, Rosemonde Bolarinwa, Oladimeji Akeem Tou, Fatoumata de Haan, Freek Dhorda, Mehul Dondorp, Arjen M. Amaratunga, Chanaki Mokuolu, Olugbenga Ayodeji Ouedraogo, Jean Bosco Cheah, Phaik Yeong |
author_facet | Tindana, Paulina Guissou, Rosemonde Bolarinwa, Oladimeji Akeem Tou, Fatoumata de Haan, Freek Dhorda, Mehul Dondorp, Arjen M. Amaratunga, Chanaki Mokuolu, Olugbenga Ayodeji Ouedraogo, Jean Bosco Cheah, Phaik Yeong |
author_sort | Tindana, Paulina |
collection | PubMed |
description | BACKGROUND: Artemisinin-based combination therapies (ACTs) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in all malaria endemic countries. Artemisinin resistance, partner drug resistance, and subsequent ACT failure are widespread in Southeast Asia. The more recent independent emergence of artemisinin resistance in Africa is alarming. In response, triple artemisinin-based combination therapies (TACTs) are being developed to mitigate the risks associated with increasing drug resistance. Since ACTs are still effective in Africa, where malaria is mainly a paediatric disease, the potential deployment of TACTs raises important ethical questions. This paper presents an analysis of stakeholders’ perspectives regarding key ethical considerations to be considered in the deployment of TACTs in Africa provided they are found to be safe, well-tolerated and effective for the treatment of uncomplicated malaria. METHODS: We conducted a qualitative study in Burkina Faso and Nigeria assessing stakeholders’ (policy makers, suppliers and end-users) perspectives on ethical issues regarding the potential future deployment of TACTs through 68 in-depth interviews and 11 focus group discussions. FINDINGS: Some respondents suggested that there should be evidence of local artemisinin resistance before they consider deploying TACTs, while others suggested that TACTs should be deployed to protect the efficacy of current ACTs. Respondents suggested that additional side effects of TACTs compared to ACTs should be minimal and the cost of TACTs to end-users should not be higher than the cost of current ACTs. There was some disagreement among respondents regarding whether patients should have a choice of treatment options between ACTs and TACTs or only have TACTs available, while ACTs are still effective. The study also suggests that community, public and stakeholder engagement activities are essential to support the introduction and effective uptake of TACTs. CONCLUSION: Addressing ethical issues regarding TACTs and engaging early with stakeholders will be important for their potential deployment in Africa. |
format | Online Article Text |
id | pubmed-9462557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-94625572022-09-10 Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria Tindana, Paulina Guissou, Rosemonde Bolarinwa, Oladimeji Akeem Tou, Fatoumata de Haan, Freek Dhorda, Mehul Dondorp, Arjen M. Amaratunga, Chanaki Mokuolu, Olugbenga Ayodeji Ouedraogo, Jean Bosco Cheah, Phaik Yeong PLoS One Research Article BACKGROUND: Artemisinin-based combination therapies (ACTs) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in all malaria endemic countries. Artemisinin resistance, partner drug resistance, and subsequent ACT failure are widespread in Southeast Asia. The more recent independent emergence of artemisinin resistance in Africa is alarming. In response, triple artemisinin-based combination therapies (TACTs) are being developed to mitigate the risks associated with increasing drug resistance. Since ACTs are still effective in Africa, where malaria is mainly a paediatric disease, the potential deployment of TACTs raises important ethical questions. This paper presents an analysis of stakeholders’ perspectives regarding key ethical considerations to be considered in the deployment of TACTs in Africa provided they are found to be safe, well-tolerated and effective for the treatment of uncomplicated malaria. METHODS: We conducted a qualitative study in Burkina Faso and Nigeria assessing stakeholders’ (policy makers, suppliers and end-users) perspectives on ethical issues regarding the potential future deployment of TACTs through 68 in-depth interviews and 11 focus group discussions. FINDINGS: Some respondents suggested that there should be evidence of local artemisinin resistance before they consider deploying TACTs, while others suggested that TACTs should be deployed to protect the efficacy of current ACTs. Respondents suggested that additional side effects of TACTs compared to ACTs should be minimal and the cost of TACTs to end-users should not be higher than the cost of current ACTs. There was some disagreement among respondents regarding whether patients should have a choice of treatment options between ACTs and TACTs or only have TACTs available, while ACTs are still effective. The study also suggests that community, public and stakeholder engagement activities are essential to support the introduction and effective uptake of TACTs. CONCLUSION: Addressing ethical issues regarding TACTs and engaging early with stakeholders will be important for their potential deployment in Africa. Public Library of Science 2022-09-09 /pmc/articles/PMC9462557/ /pubmed/36083995 http://dx.doi.org/10.1371/journal.pone.0273249 Text en © 2022 Tindana et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Tindana, Paulina Guissou, Rosemonde Bolarinwa, Oladimeji Akeem Tou, Fatoumata de Haan, Freek Dhorda, Mehul Dondorp, Arjen M. Amaratunga, Chanaki Mokuolu, Olugbenga Ayodeji Ouedraogo, Jean Bosco Cheah, Phaik Yeong Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria |
title | Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria |
title_full | Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria |
title_fullStr | Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria |
title_full_unstemmed | Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria |
title_short | Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria |
title_sort | ethical considerations in deploying triple artemisinin-based combination therapies for malaria: an analysis of stakeholders’ perspectives in burkina faso and nigeria |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462557/ https://www.ncbi.nlm.nih.gov/pubmed/36083995 http://dx.doi.org/10.1371/journal.pone.0273249 |
work_keys_str_mv | AT tindanapaulina ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria AT guissourosemonde ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria AT bolarinwaoladimejiakeem ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria AT toufatoumata ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria AT dehaanfreek ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria AT dhordamehul ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria AT dondorparjenm ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria AT amaratungachanaki ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria AT mokuoluolugbengaayodeji ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria AT ouedraogojeanbosco ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria AT cheahphaikyeong ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria |